Lanzoni Monica, Fornili Marco, Felicetta Irene, Maiavacca Rita, Biganzoli Elia, Castaldi Silvana
Quality Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
J Eval Clin Pract. 2017 Jun;23(3):654-661. doi: 10.1111/jep.12696. Epub 2017 Jan 12.
RATIONALE, AIMS AND OBJECTIVES: The increasing number of diagnostic tests requests all over the world is a problem that can partially be explained by inappropriate testing. Impact on the total costs of health systems becomes relevant when tests are performed in a large amount. In this paper, retesting of total cholesterol, ferritin, vitamin B , vitamin D, and folate is assessed.
The Quality Unit of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano (Fondazione) decided to perform a first assessment of the appropriate use of the laboratory tests cholesterol, ferritin, vitamin B , vitamin D, and folate focusing on the retesting interval for the same patient in the time period January 1, 2012, to December 31, 2014, in every care setting. The minimum retesting intervals were chosen following the ACB recommendations. The Fondazione is a research and teaching hospital with 3 emergency units (adult, pediatric, and obstetric), kidney, liver, lung, cornea, and bone marrow transplant centers and a medical school. Record linkage of laboratory records selected for the time interval January 1, 2012, to December 31, 2014, was applied using tax code. For each marker, the distribution of retesting intervals was evaluated for every year and the total period. With the same record linkage variable, requests on inpatients were identified from hospital discharge records. A cost analysis of inappropriate retesting was performed for every test.
We examined 466 035 requests for 113 019 patients. Proportions of tests judged potentially inappropriate varied between 8.1% for 1,25-dihydroxy vitamin D and 37.1% for total cholesterol. The rates of inappropriate tests from year to year never showed significant decrease, and the maximum increase corresponded to an odds ratio of 1.85 (95% CI, 1.36-2.51) for 1,25-dihydroxy vitamin D from 2012 to 2013. Calculated loss of money was approximately €500 000 in the 3 years.
Inappropriate requests represent a waste of time and money resources. Our analysis highlighted economically unacceptable rates of inappropriate retesting, with no evidence of decreasing trend. Actions to raise awareness in clinicians or automated electronic solutions are necessary to limit unnecessary test repetitions.
原理、目的和目标:全球诊断检测请求数量不断增加,这一问题部分可归因于检测不当。当大量进行检测时,对卫生系统总成本的影响就变得显著。本文评估了总胆固醇、铁蛋白、维生素B、维生素D和叶酸的重新检测情况。
米兰大学附属圣心综合医院基金会(Fondazione)质量部门决定对2012年1月1日至2014年12月31日期间同一患者在各个医疗环境中胆固醇、铁蛋白、维生素B、维生素D和叶酸等实验室检测的合理使用情况进行首次评估。根据ACB建议选择了最短重新检测间隔时间。Fondazione是一家教学医院,设有3个急诊科(成人、儿科和产科)、肾脏、肝脏、肺、角膜和骨髓移植中心以及一所医学院。利用税务代码对2012年1月1日至2014年12月31日期间选定的实验室记录进行记录链接。对于每个指标,评估每年以及整个时间段内重新检测间隔的分布情况。利用相同的记录链接变量,从医院出院记录中识别住院患者的检测请求。对每项检测进行了不适当重新检测的成本分析。
我们检查了113019名患者的466035份检测请求。判定可能不适当的检测比例在1,25 - 二羟基维生素D的8.1%至总胆固醇的37.1%之间变化。每年不适当检测率从未显著下降,最大增幅对应2012年至2013年1,25 - 二羟基维生素D的优势比为1.85(95%置信区间,1.36 - 2.51)。3年计算得出的资金损失约为50万欧元。
不适当的请求是对时间和资金资源的浪费。我们的分析突出了不适当重新检测在经济上不可接受的比率,且没有下降趋势的证据。有必要采取行动提高临床医生的意识或采用自动化电子解决方案,以限制不必要的检测重复。